


Acolbifene

Cat. No.:	HY-16023A		
CAS No.:	182167-02-8		
Molecular Formula:	C ₂₉ H ₃₁ NO ₄		
Molecular Weight:	457.56		
Target:	Estrogen Receptor/ERR		
Pathway:	Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (109.28 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.1855 mL	10.9275 mL	21.8551 mL
5 mM	0.4371 mL	2.1855 mL	4.3710 mL
10 mM	0.2186 mL	1.0928 mL	2.1855 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Acolbifene (EM-652), the active metabolite of EM800, is an orally active pure antiestrogen and selective estrogen receptor antagonist. Acolbifene (EM-652) inhibits estradiol (E2)-induced transcriptional activity of ER α (IC₅₀ = 2 nM) and ER β (IC₅₀ = 0.4 nM). Acolbifene (EM-652) possesses potent and pure anticarcinogenic properties^{[1][2][3][4][5]}.

IC₅₀ & Target

ER α 2 nM (IC ₅₀ , E2-induced transcriptional activity)	ER β 0.4 nM (IC ₅₀ , E2-induced transcriptional activity)
--	---

In Vitro

Acolbifene (ACOL) does not affect pathways of cholesterol synthesis, supporting the involvement of the clearance-related receptors in its hypocholesterolemic action^[2].

Acolbifene (EM-652) shows no agonistic activity on ER α and ER β transcriptional function and blocks the estradiol (E2)-mediated activation of both ER α and ER β ^[3].

Acolbifene (EM-652) shows the most potent inhibition of estradiol-stimulated cell proliferation in human breast cancer cells (ZR-75-1, MCF-7, T-47D) and is devoid of any intrinsic estrogenic activity^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Acolbifene (ACOL) reduces food intake and strongly decreases cholesterolemia in rats fed a cholesterol-free diet^[2]. Acolbifene (ACOL) reduces food intake (16%) and weight gain (45%, mainly fat) similarly in both dietary cohorts^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (n = 42) initially weighing 175-200 g ^[2] .
Dosage:	2.5 mg/kg.
Administration:	Oral gavage, once daily for 21 d.
Result:	Prevents tumor growth in rats.

CUSTOMER VALIDATION

- Int J Mol Sci. 2022 Oct 6;23(19):11892.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Wang T, et al. Recent advances in selective estrogen receptor modulators for breast cancer. *Mini Rev Med Chem*. 2009 Sep;9(10):1191-201.
- [2]. Christian Lemieux, et al. The selective estrogen receptor modulator acolbifene reduces cholesterolemia independently of its anorectic action in control and cholesterol-fed rats. *J Nutr*. 2005 Sep;135(9):2225-9.
- [3]. A Tremblay, et al. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. *Endocrinology*. 1998 Jan;139(1):111-8.
- [4]. Sylvain Gauthier, et al. Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. *J Enzyme Inhib Med Chem*. 2005 Apr;20(2):165-77.
- [5]. F Labrie, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. *J Steroid Biochem Mol Biol*. Apr-Jun 1999;69(1-6):51-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA